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Abstract
SIRT1, an NAD
+ (nicotinamide adenine dinucleotide)-dependent deacetylase, protects cells from stress-induced apoptosis,
and its orthologues delay aging in lower eukaryotes. SIRT1 increases survival in response to stress such as DNA damage by
deacetylating a number of substrates including pro-apoptotic protein p53. The molecular mechanism by which DNA-
damage activates SIRT1 is not known. By screening a kinase inhibitor library, we identified CK2 as a SIRT1 kinase. CK2 is a
pleiotropic kinase with more than 300 substrates and well-known anti-apoptotic and pro-growth activities. We find that CK2
is recruited to SIRT1 after ionizing radiation (IR) and phosphorylates conserved residues Ser 154, 649, 651 and 683 in the N-
and C-terminal domains of mouse SIRT1. Phosphorylation of SIRT1 increases its deacetylation rate but not if the four Ser
residues are mutated. In addition, phosphorylation of SIRT1 increases its substrate-binding affinity. CK2-mediated
phosphorylation increases the ability of SIRT1 to deacetylate p53 and protect cells from apoptosis after DNA damage. Based
on these findings, we propose that CK2 protects against IR-induced apoptosis partly by phosphorylating and activating
SIRT1. Thus, this work suggests that SIRT1 is a component of the expansive anti-apoptotic network controlled by CK2. Since
expression of both CK2 and SIRT1 is upregulated with tumorigenesis and downregulated with senescence, the CK2-SIRT1
link sheds new light on how CK2 may regulate cancer development and aging.
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Introduction
Sirtuins [1], which are composed of seven members (SIRT1-
SIRT7),are class III histone/protein deacetylases (HDAC).Unlike the
other classes of HDACs, they require the coenzyme NAD+
(nicotinamide adenine dinucleotide) [2,3]. Sirtuins are orthologs of
yeast Sir2 (silencing information regulator) [2,3], which mediates
chromatin silencing [4,5] and slows the aging rate by suppressing the
production of extrachromosomal rDNA circles [6]. Within the Sirtuin
family, SIRT1 [7] is most closely related to yeast Sir2. Calorie
restriction, the only known intervention that extends life span in
mammals, increases SIRT1 expression in some tissues [8,9]. There is
no evidence that SIRT1 regulates aging in mammals, but it does
increase resistance to various forms of stress [8,10,11,12,13,14]. One
very well characterized pathway regulated by SIRT1 is DNA-damage
induced apoptosis. SIRT1 deacetylates and decreases the transcrip-
tional activity of pro-apoptotic p53 and increases cell survival after
DNA damage [12,15,16,17]. Consistent with the pro-survival function
of SIRT1, p53 is hyperacetylated in mice lacking SIRT1, and
thymocytes derived from these mice have increased sensitivity to IR
[15]. However, the biochemical pathway that activates SIRT1 in
response to DNA damage has not been discovered.
CK2, a tetrameric enzyme composed of two catalytic subunits (aa,
aa’o ra’a’) and two regulatory b subunits, is a ubiquitously expressed
and evolutionarily conserved serine/threonine protein kinase [18].
CK2a and CK2a’ have approximately 90% identity in their catalytic
domains and have similar enzymatic properties including substrate
specificity. CK2 is a pleiotropic kinase that has more than 300
putative targets [19] and can be found in the nucleus, cytoplasm and
specific structures and organelles such as the plasma membrane,
Golgi, ribosomes and endoplasmic reticulum [20]. CK2 is essential
for viability [21] and plays a critical role in tumor development [22].
Phosphorylation by CK2 prevents caspase-mediated cleavage of a
number ofproteinsinvolved intheregulation of cellsurvival [23], and
suppression of CK2 decreases cell proliferation and viability [24,25].
Although CK2 has a high basal activity, it can be stimulated with
growth factors [26], serum [27] and stresses such as DNA damage
[28,29]. CK2 function is also modulated by translocation to specific
sites within the cell. For example, stresses such as ionizing radiation
IR [25] and hypoxia [30] cause nuclear accumulation of CK2.
Here, we report that IR leads to CK2-SIRT1 interaction and
CK2-mediated phosphorylation at four Ser residues. SIRT1
phosphorylation increases its substrate-binding affinity and its
deacetylase activity. As a result, SIRT1 phosphorylation increases
p53 deacetylation and survival after DNA-damage.
Results and Discussion
SIRT1 phosphorylation is CK2-dependent
Phosphorylation is one of the most common mechanisms by
which protein function is regulated. To identify a potential kinase
that phosphoryates SIRT1, we screened a library of 81 kinase-
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32P
incorporation into SIRT1. We incubated HEK 293T cells stably
expressing WT Flag-tagged mouse SIRT1 in 100 mCi/ml [
32P]-
orthophosphoric acid for one hr and isolated SIRT1 by
immunoprecipitating with anti-FLAG antibody (Fig. 1A). From
this screen, we identified four kinase-inhibitors that suppressed
SIRT1 phosphorylation by more than 50%: Staurosporin (pan-
specific), by 86.6%; Tyrphostin 9 (PDGF receptor kinase
inhibitor), by 79.8%; GW 5074 (c-Raf inhibitor), by 74.5%;
TBCA (the most potent CK2 inhibitor) [31], by 72.5%. Two other
CK2 inhibitors used in this screen, DRB and Apigenin, did not
significantly inhibit
32P incorporation because of weak inhibitory
activity at the concentration that we used here. We also tested
whether inhibitors of other growth or stress-related kinases that
were not included in the screen affected
32P incorporation into
SIRT1. As shown in Fig. 1B, only TBCA inhibited
32P
incorporation into SIRT1.
The localization of PDGF receptor and c-Raf are limited to the
plasma membrane and cytoplasm, respectively, whereas CK2 can
be found in the nucleus, cytoplasm and specific structures and
organelles such as the plasma membrane, Golgi, ribosomes and
endoplasmic reticulum [20]. Although SIRT1 has been detected
in both cytoplasm and nucleus in some cell types [32,33], SIRT1 is
a nuclear protein in most cell lines [34,35], including the HEK
293T cell line that we used for this kinase inhibitor screen (data not
shown). Based on common nuclear localization, we chose to
investigate the possibility that CK2 is a SIRT1 kinase.
Identification of CK2 phosphorylation sites in SIRT1
To investigate whether CK2 phosphorylates SIRT1 directly, we
produced fragments of mouse SIRT1 proteins in E. coli and
performed in vitro kinase reactions using CK2 a(Fig. 2A). We found
that CK2 phosphorylation sites were located in N-terminal (a.a. 1–
235) and C-terminal (a.a. 611–737) domains but not in the Sirtuin
(deacetylase) domain (Fig. 2B). The consensus sequence for CK2
phosphorylation is S/TXXD/E, where X can be any amino acid
residue. There are four evolutionarily-conserved CK2 consensus
sequences (Ser 154,649,651,683) within the CK2 phosphorylated
regions of SIRT1 (*, Fig. 2C). To identify the CK2 phosphory-
lation sites, we mutated the four CK2 consensus sites to Ala either
individually or in groups (Fig. 2D–I). Mutating Ser 154 to Ala
(S154A) completely abolished CK2 phosphorylation of the N-
terminal fragment indicating that Ser 154 is the only CK2
phosphorylation site in the N-terminal fragment (Fig. 2D).
Mutating Ser 649 to Ala (S649A) in the C-terminal fragment
significantly reduced SIRT1 phosphorylation but did not abolish it
(Fig. 2E). Mutating Ser 651 to Ala (S651A) in fragment CT-2
consistently reduced SIRT1 phosphorylation, albeit slightly
(Fig. 2F). Mutating Ser 649 and 651 to Ala decreased
phosphorylation of full-length SIRT1 more than mutating Ser
649 alone, indicating that both Ser 649 and 651 are phosphor-
ylated by CK2 (Fig. 2G). Mutating Ser 649, 651 and 683 to Ala in
the C-terminal fragment completely abolished phosphorylation of
the C-terminal fragment but mutating Ser 649 and 651 did not,
indicating that Ser 683 is also phosphorylated by CK2 (Fig. 2H).
Mutating Ser 154, 649, 651 and 683 (4A) completely abolished
CK2 phosphorylation of full-length SIRT1 (Fig. 2I), indicating
that CK2 phosphorylates all four conserved Ser residues in vitro.
CK2-mediated phosphorylation of SIRT1 in vivo
To confirm that the four Ser residues were phosphorylated in
vivo, we performed the [
32P]-orthophosphoric acid incorporation
assay after transiently expressing wild-type (WT) and 2A (S649/
651A) and 4A (S154/649/651/683A) mutant SIRT1 in HEK
Figure 1. SIRT1 phosphorylation is CK2-dependent. (A) HEK 293T cells stably expressing Flag-tagged SIRT1 protein were incubated with
32P
orthophosphoric acid and the indicated protein kinase inhibitor (10 mM) (see Table S1). Each bar represents the intensity of phosphorylated SIRT1
normalized to the total SIRT1 level after immunoprecipitation (IP) with M2 Flag antibody. The value of vehicle-treated sample was set to 100%. (B)I n
vivo
32P labeling of SIRT1 in the presence of inhibitors of stress-activated kinases that are indicated.
doi:10.1371/journal.pone.0006611.g001
CK2 Activates SIRT1
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mutants showed progressively decreasing phosphorylation inten-
sity. Even in 4A mutant, there was some residual phosphorylation,
indicating that other kinase(s) also phosphorylate SIRT1 in vivo.T o
directly visualize phosphorylation at these four Ser residues, we
attempted to make phospho-specific antibodies recognizing each
of the four phosphorylated Ser residues. However, due to the
acidic nature of some of these sites, we were able to make a
phospho-specific antibody only for Ser 649 (Ser 659 in human
SIRT1). To test the specificity of the phospho-S649 (P-S649)
antibody, we performed CK2 kinase reactions using either WT or
4A SIRT1 as substrates with or without TBCA in the reaction
mixture. As shown in Fig. 3B, P-S649 antibody recognized SIRT1
phosphorylated by CK2 in vitro but not 4A SIRT1. P-S649
antibody also recognized WT but not 4A SIRT1 in transiently
transfected cells (Fig. 3C). Ser 649 phosphorylation of endogenous
SIRT1 was poorly visible in untreated cells but was induced
90 min after IR (Fig. 3D). The interaction between SIRT1 and the
two catalytic subunits of CK2 also increased significantly 90 min
after IR (Fig. 3D). To demonstrate that SIRT1 phosphorylation is
mediated by CK2, we transiently expressed SIRT1 along with
siRNA for either a scrambled sequence or for both catalytic
subunits of CK2 (a and a’). Two hours before they were harvested,
cells were exposed to IR to induce Ser 649 phosphorylation.
Knock-down of CK2 dramatically reduced Ser 649 phosphory-
lation, indicating that CK2 phosphorylates Ser 649 in vivo (Fig. 3E).
In agreement with this, treatment of cells with CK2-inhibitor
TBCA (Fig. 3F) or coexpression of kinase-dead (KD) CK2 a’
(Fig. 3G) significantly inhibited Ser 649 phosphorylation. Our
inability to detect Ser 649 phosphorylation in endogenous SIRT1
Figure 2. Identification of CK2 phosphorylation sites in mouse SIRT1. (A) Diagram of recombinant mouse SIRT1 fragments produced in
E.coli. The a.a. number of the first and last a. a. for each fragment is as indicated. (B) SIRT1 fragments from (A) were incubated with CK2 a and
32P[c-
ATP], subjected to SDS-PAGE, Coomassie staining and autoradiography. GST-PC, which contains the optimized CK2 phosphorylation site, was used as
a positive control. (C) Evolutionarily conserved CK2 consensus sites located in the fragments phosphorylated by CK2 are marked (*). (D–H) Indicated
Ser (S) residues in SIRT1 fragments (see Fig. 2A ) were mutated to Ala (A) individually or in combination. Fragments containing the mutation were
incubated with CK2 a and
32P[c-ATP] and then subjected to SDS-PAGE, Coomassie staining and autoradiography. (I) CK2-dependent phosphorylation
of full-length (FL) and S154/649/651/683A (4A) mutant SIRT1 in vitro. CK2 phosphorylation was performed and visualized as in (B).
doi:10.1371/journal.pone.0006611.g002
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activity and also because we did not use IR when we discovered
through our kinase inhibitor screen (Fig. 1) that TBCA inhibited
SIRT1 phosphorylation. We believe that this apparent contradic-
tion is due to the low sensitivity of P-S649 antibody. Ser 649
phosphorylation is visible in transiently expressed SIRT1 because
there is more SIRT1 protein in the cell and the vector DNA
triggers the DNA-break signal in the way IR does (data not
shown).
To determine how phosphorylation by CK2 affects SIRT1, we
measured the deacetylase activity of SIRT1 after CK2 phosphor-
ylation in vitro. Deacetylation of Lys 382 in p53, which is known to
be mediated by SIRT1 [16], was used as the indicator for SIRT1
activity. We monitored p53 deacetylation after 20, 40 or 60 min
reaction time (Fig. 4A). For all three reaction times, deacetylation
of p53 by WT SIRT1 was increased after CK2 phosphorylation,
but not if TBCA was present during the phosphorylation reaction.
However, deacetylation of p53 by 4A SIRT1 was not affected by
CK2. It should be noted that in the absence of CK2
phosphorylation, the deacetylase activity of 4A SIRT1 is
comparable to that of WT SIRT1, indicating that the four Ser
residues are not essential for SIRT1 activity in vitro.
Phosphorylation by CK2 activates SIRT1
In response to DNA damage, Lys 382 in p53 is acetylated by
histone acetyltransferase p300 [36,37]. Acetylation of p53
increases its affinity to the target DNA sequence and thus its
transcriptional activity. We investigated the effect of CK2 on
SIRT1 activity in U2OS cells using p53 (K382) acetylation as the
endogenous marker for the deacetylase activity of SIRT1. The
acetylation level of K382 at any given moment is determined by
the rate of acetylation and deacetylation at that moment. To
determine the time course of CK2-mediated activation of SIRT1,
we visualized acetylation of K382 at different time points after IR
in cells transfected with siRNA for either a scrambled sequence or
for both catalytic subunits of CK2 (Fig. 4B). Consistent with the
observation that acetylation of K382 by p300 occurs 2 hr after IR
[37], K382 acetylation peaked 2 hr after IR. However, K382
acetylation at 2 hr was higher when CK2 was knocked-down and
did not return to baseline even at 7 hr, indicating that CK2
increases the deacetylase activity of SIRT1. Although CK2
enhanced SIRT1 activity at 2 hr point, the acetylation level of
K382 at this time is still higher than before IR, suggesting that
p300 activity exceeds SIRT1 activity at 2 hr point. Although this
experiment suggests that CK2-activated SIRT1 deacetylated p53,
we cannot rule out the possibility that activated SIRT1 decreased
p53 acetylation by an indirect mechanism, such as improved DNA
repair leading to reduced p300-mediated acetylation of p53.
However, as of now, there is no evidence that SIRT1 improves
DNA repair.
In order to confirm that CK2 phosphorylation increases SIRT1
activity, we transiently expressed p53 along with WT SIRT1 or 4A
SIRT1 in H1299 cells and monitored p53 acetylation. The
deacetylase activity of WT SIRT1 was inhibited in the presence of
Figure 3. CK2 phosphorylates SIRT1 after ionizing radiation. (A) V5-tagged WT SIRT1, 2A (S649/651A) SIRT1 and 4A (S154/649/651/683A)
SIRT1 expression plasmids were transfected into HeLa cells and labeled with
32P orthophosphoric acid for 2 hrs. After labeling, V5-SIRT1 was
immunoprecipitated.
32P-labeled SIRT1 was detected by autoradiography and the total level of SIRT1, by immunoblotting (IB) with SIRT1 antibody.
(B) Recombinant full-length WT and 4A SIRT1 were phosphorylated by CK2 with DMSO (2) or with TBCA (20 mM). Immunoblotting was performed
with S649-specific phospho-antibody (P-S649). Total SIRT1 levels are shown below. (C) Transiently expressed V5-WT or 4A SIRT1 was
immunoprecipitated with V5 antibody and immunoblotted with P-S649 antibody. Immunoprecipitation with HA antibody was used as a control.
(D) HeLa cells were harvested 60 and 90 min after IR (20 Gy) and endogenous SIRT1 was immnoprecipitated with either SIRT1 antibody or a control
antibody, IgG. Immunoblotting was performed with P-S649 antibody to visualize SIRT1 phosphorylation and with SIRT1 antibody to visualize total
SIRT1 levels. SIRT1-CK2 interaction was visualized by immunoblotting with antibody specific for CK2 a or CK2 a’. (E) Flag-tagged WT SIRT1 transiently
expressed in HeLa cells with siRNA for either a scrambled sequence (Scr) or both catalytic subunits of CK2. Two hr after IR (20 Gy), SIRT1 was
immunoprecipitated and then immunoblotted with P-S649 to visualize CK2 phosphorylation. (F) Lysates from HeLa cells co-expressing Flag-tagged
WT SIRT1 treated with DMSO (2) or with 20 mM TBCA (+) starting 1 hr before IR (20 Gy). Two hr after IR, SIRT1 was immunoprecipitated with Flag
antibody and then immunoblotted with P-S649 antibody. (G) Lysates from HeLa cells co-expressing Flag-tagged WT SIRT1 and either WT or KD CK2
were harvested 2 hr after IR. SIRT1 was immunoprecipitated with a Flag antibody and then immunoblotted with P-S649 antibody.
doi:10.1371/journal.pone.0006611.g003
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than that of WT SIRT1, was insensitive to TBCA (Fig. 4C). Since
there is a possibility that the effect of TBCA on SIRT1 activity was
due to an off-target hit of TBCA, we overexpressed kinase-dead
(KD) CK2 a’ to inhibit the CK2 activity in a dominant-negative
fashion (Fig. 4D). The deacetylase activity of WT SIRT1 as
measured by p53 deacetylation was suppressed in the presence of
KD CK2 a’, but the deacetylase activity of 4A SIRT1 was not
affected by KD CK2 a’. To determine if CK2 regulates
deacetylation of other SIRT1 substrates, we repeated the
experiment using RelA/p65 subunit of NF-kB, another known
SIRT1 substrate (Fig. 4E) [38]. The deacetylase activity of WT
SIRT1, as measured by RelA/p65 deacetylation, was suppressed
in the presence of KD CK2 a’, but the deacetylase activity of 4A
SIRT1 was not affected by KD CK2 a’. We also tried to knock-
down CK2 using siRNA specific for the catalytic subunits of CK2
in cells transiently expressing either WT or 4A SIRT1. However,
we noticed that the combination of CK2 siRNA and 4A SIRT1
expression caused cell death, and therefore did not continue this
experiment. Thus, CK2-dependent phosphorylation of SIRT1
stimulates the deacetylase activity of SIRT1 against at least two
known substrates, p53 and NF-kB.
Phosphorylation by CK2 increases SIRT1 substrate-
binding
Since the CK2 phosphorylation sites are distant from the Sirtuin
domain of SIRT1, it is curious that deacetylation of its substrate is
increased by CK2 phosphorylation. One possibility is that SIRT1
phosphorylation changes its substrate binding affinity. To investigate
whether phosphorylation by CK2 affects SIRT1-substrate interac-
tion, we performed a GST-pull down assay using acetylated GST-
p53 fusion protein and WT or 4A mutant SIRT1 that has been
preincubated with CK2. As shown in Fig. 5, preincubation of WT
SIRT1 with CK2 increased WT SIRT1-p53 interaction in a TBCA-
sensitive manner. In contrast, preincubation of 4A SIRT1 with CK2
did not affect SIRT1-p53 interaction. To determine if acetylation of
Figure 4. CK2 phosphorylation stimulates SIRT1 activity. (A) Deacetylase activity of recombinant WT or 4A SIRT1 that was phosphorylated
with CK2 in the presence or absence of TBCA (20 mM). Deacetylase activity of SIRT1 was visualized by immunoblotting with acetylated p53 (K382)
antibody. The total level of p53 is visualized by Ponceau staining the total level of SIRT1 is visualized by immunoblotting with SIRT1 antibody. (B) The
deacetylase activity of the endogenous SIRT1 in the presence of siRNA for either a scrambled sequence or for both catalytic subunits of CK2. P53 K382
acetylation was visualized 2 and 7 hr after IR (20Gy) in U2OS cells. Total levels of p53, SIRT1, CK2a, CK2a’ and actin are shown below. (C) H1299 cells
co-expressing V5-tagged WT or 4A SIRT1 and p53 in the presence or absence of TBCA were harvested 6 hr after IR (20 Gy). Acetylation of p53 was
visualized by immunoblotting with acetylated p53 (K382) antibody. (D) V5-tagged WT or 4A SIRT1 was transiently co-expressed with p53 and either
HA-tagged WT or KD CK2a’ in H1299 cells. Cells were harvested 6 hr after IR and deacetylation of p53 was visualized by immunoblotting with
acetylated p53 (K382) antibody. (E) V5-tagged WT or 4A SIRT1 was transiently co-expressed with FLAG-RelA/p65 (a component of NF-kB) and either
HA-tagged WT or KD CK2a’ in H1299 cells. FLAG-RelA/p65 was immunoprecipitated with FLAG antibody and immunoblotted with either FLAG
antibody to visualize the total level of FLAG-RelA/p65 or Ac-Lys antibody to visualize the acetylation level.
doi:10.1371/journal.pone.0006611.g004
CK2 Activates SIRT1
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also performed the GST-pull down assay using unacetylated GST-
p53. CK2-mediated phosphorylation increased SIRT1 interaction
with unacetylated GST-p53 (Fig. 5, bottom), indicating that the
acetyl-group on the substrate is not a feature that is required for the
enhanced affinity. Taken together, these findings indicate that one
mechanism by which CK2-mediated phosphorylation increases
SIRT1 deacetylase activity is increasing interaction with its substrate.
We cannot rule out the possibility that CK2-mediated phosphory-
lation also increases SIRT1 activity by other mechanisms.
Anti-apoptotic function of SIRT1 is enhanced by CK2-
mediated phosphorylation
SIRT1 protects cells from apoptosis induced by DNA damage
[11,12,14,16]. The most commonly studied role of SIRT1 in stress
resistance is p53 deacetylation and suppression of p53-induced
apoptosis. To measure the effect of CK2-mediated phosphoryla-
tion of SIRT1 on p53 mediated apoptosis, H1299 cells were co-
transfected with p53 and either WT or 4A SIRT1 and treated with
the genotoxin etoposide for 24 hr. Quantification of apoptosis
indicated that WT SIRT1 suppressed etoposide-induced apoptosis
by 42% and 4A SIRT1, by 16%, compared to vector (pcDNA)-
alone control (Fig. 6A). Thus, the CK2 phosphorylation sites are
important for the anti-apoptotic effects of SIRT1. Since the 4A
mutation does not significantly affect the intrinsic SIRT1 activity
(see Fig. 4A), the low magnitude of the anti-apoptotic effect of 4A
SIRT1 is most likely due to the baseline protection from
endogenous SIRT1 in all the samples. Deacetylation of p53 was
significantly stronger with WT SIRT1 than with 4A SIRT1
(Fig. 6B) in these cells. Collectively, these results suggest that the
anti-apoptotic function of SIRT1 is enhanced by CK2-mediated
phosphorylation.
Despite the prominent role of SIRT1 in DNA damage-
response, the signaling pathway that activates SIRT1 after
DNA-damage was unknown. Our results indicate that CK2
activates SIRT1 by phosphorylating four Ser residues in N- and C-
terminal domains. Although very little is known about the function
of the N- and C-terminal domains of SIRT1, our finding that
CK2-mediated phosphorylation increases SIRT1-p53 interaction
suggests that the N- and C-terminal domains regulate substrate
recruitment. A full understanding of how these terminal domains
and their phosphorylation regulate SIRT1 function is hampered
by the lack of 3D structure information on the full-length SIRT1
or on the terminal domains. It remains to be determined whether
CK2-mediated phosphorylation affects SIRT1 activity by simply
increasing substrate recruitment or whether other mechanisms are
also involved.
To our knowledge, this work represents the first identification of
a signal pathway that activates the catalytic function of SIRT1 in
response to DNA damage. While this work was in progress,
Zschoernig et. al. [39] reported that CK2 phosphorylates Ser 649/
651 but did not determine whether phosphorylation affected
SIRT1 in any way or under what conditions CK2 phosphorylates
SIRT1. Also, Sasaki et. al. [40] reported that SIRT1 is activated
by phosphorylation at multiple sites and two of these sites (Thr 530
and Ser 540 in human SIRT1) are phosphorylated by cyclinB/
Cdk1, and mutation of these residues disturbed cell cycle
Figure 5. Phoshorylation by CK2 increases SIRT1-p53 interac-
tion. GST-pull down experiment was performed with GST-p53
(acetylated) using WT (top) and 4A SIRT1 (center) phosphorylated with
CK2 with or without TBCA. The same experiment using unacetylated
GST-p53 and WT SIRT1 is shown at the bottom.
doi:10.1371/journal.pone.0006611.g005
Figure 6. CK2 phosphorylation confers increased SIRT1-mediated survival after genotoxic treatment. (A) H1299 cells transiently
expressing p53 and either WT or 4A SIRT1 were treated with the genotoxin etoposide (20 mM) for 24 hr. Apoptosis was quantified by cell death
detection ELISA
PLUS. Data are represented as mean6SEM. **, p,0.01 between WT SIRT1 and pcDNA (n=3). #,p ,0.05 between 4A SIRT1 and pcDNA
(n=3). (B) Deacetylation of p53 in etoposide-trated cells was visualized in cells expressing p53 and either WT or 4A SIRT1 by immunoblotting with
acetylated p53 (K382) antibody.
doi:10.1371/journal.pone.0006611.g006
CK2 Activates SIRT1
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did not affect the catalytic activity of SIRT1. Thus, it is not clear
how phosphorylation by cyclinB/Cdk1 activates SIRT1 activity.
Interestingly, SIRT1 activity is activated by sumoylation of Lys
734 [13]; and DNA-damage causes SENP1-mediated desumoyla-
tion and inhibition of SIRT1 activity. SIRT1 activity is also
regulated by proteins that bind SIRT1 directly. AROS, which
binds to the N-terminal domain of SIRT1, activates SIRT1 [41].
It is not known if AROS-SIRT1 interaction is regulated by DNA
damage or other forms of stress. In contrast, DBC1, which binds to
the Sirtuin domain of SIRT1, inhibits SIRT1 activity in response
to DNA-damage [11,14]. Thus, these previous reports and our
findings indicate that DNA-damage has both inhibitory and
stimulatory effects on SIRT1 activity.
Previous studies have shown that CK2 can phosphorylate Ser
392 [42] of p53 and enhance its activity by increasing
tetramerization and DNA binding [43]. Therefore, CK2 may
regulate p53 activity directly and indirectly through SIRT1 as we
have demonstrated here. However, Ser 392 is phosphorylated
after UV irradiation but not after IR or etoposide [28,44],
suggesting that CK2 does not phosphorylate p53 in response to
double-stranded breaks. Since we utilized IR and etoposide, not
UV, in this work, it is unlikely that direct p53 phosphorylation
played a significant role in CK2-dependent regulation of p53 that
we describe here.
Our findings show that SIRT1 is a component of an expansive
anti-apoptotic network that is controlled by CK2. Since expression
of both CK2 and SIRT1 is upregulated with tumorigenesis
[22,45,46] and downregulated with senescence [47,48], the CK2-
SIRT1 pathway is likely to play an important role in regulating
cellular survival and death associated with cancer and aging.
Although SIRT1 has anti-apoptotic functions, it may also have
anti-tumorigenesis functions as well. SIRT1 is important for
genetic stability [49], and when it is overexpressed in colonic
epithelial cells, it deacetylates b-catenin and suppresses colon
cancer cell growth [50]. Thus, SIRT1 appears to mediate a
delicate balance between its anti-growth and pro-growth proper-
ties.
Materials and Methods
Protein kinase inhibitor library screening
The kinase inhibitors were derived from the Protein kinase
inhibitor library (BIOMOL international) and other commercial
sources. HEK 293T cells stably expressing WT Flag-tagged mouse
SIRT1 were seeded onto 6 well plates at 5610
6 cells per well. One
day after plating, cells were pre-incubated with phosphate free
DMEM media (Gibco) containing 10 mM protein kinase inhibitor
for 1 hr. After pre-incubation, 100 mCi/ml [
32P]-orthophosphoric
acid was added into each well directly and incubated for another
2 hr. Labeled Flag-tagged SIRT1 proteins were immunoprecip-
itated with Flag M2-Agarose (Sigma), separated by 4–12 % SDS-
PAGE and transferred to nitrocellulose. The amounts of [
32P]-
labeled and loaded SIRT1 proteins were detected by autoradiog-
raphy and immunoblotting with SIRT1 antibody, respectively.
In vitro kinase assay
To identify CK2 phosphorylation sites, recombinant full-length
or truncated His-tagged or GST-tagged SIRT1 proteins were
incubated in kinase buffer (20 mM HEPES at pH 7.0, 10 mM
MgCl2, 1 mM DTT) containing 100 mM cold ATP, 1 mCi
(3000 mCi/mmole)
32P[c-ATP] and 20 ng CK2a enzyme (Milli-
pore) for 20 min at 30uC. Where indicated, TBCA (20 mM)
dissolved in DMSO was added to the reaction mixture.
In vitro deacetylase assay
For in vitro deacetylase assays, 2 mg purified His-tagged WT
and 4A mutant full-length SIRT1 proteins were incubated with
CK2a enzyme with or without 20 mM TBCA in a kinase buffer
described above except radioactive ATP was not included. After
the kinase reaction, the samples were loaded onto CENTRISEP
spin columns (Princeton separations) pre-equilibrated with 16PBS
to remove the excess ATP and free additives in CK2 a enzyme
solution. 1/10 volume of above phosphorylated or mock-
phosphorylated SIRT1 proteins were added to a deacetylase
buffer (50 mM HEPES at pH 7.0, 1 mM DTT, 150 mM NaCl,
protease inhibitor cocktail, and phosphatase inhibitor cocktail
(Roche)) containing 0.2 mg acetylated GST-p53, and 0.5 mM
NAD
+ in a 20 ml final reaction volume. The reactions were
performed at 37uC for the indicated durations and stopped by
adding SDS sample buffer. Heated samples were subjected to 4–
12% SDS PAGE, transferred to nitrocellulose, and immuno-
blotted with Ac-p53 (K382) antibody (Cell Signaling Technolo-
gies). The loading amounts of SIRT1 and GST-p53 proteins were
visualized with Coomassie stain and Ponceau S stain.
Acetylation of GST-p53 protein
Glutathione S-transferase (GST) fused to human p53 fragment
(amino acids 373–385) was expressed in E. coli and purified on
glutathione Sepharose beads according to the vendor’s manual.
Purified GST-p53 was acetylated by His-tagged active core p300/
CBP associated factor (PCAF, amino acids 352–832) in HAT
buffer (Millipore) containing 5 mM acetyl CoA. As shown in Fig.
S1, K382 was strongly acetylated by this method. After incubating
for 3 hrs, the reaction mixture was incubated with glutathione
Sepharose and acetylated GST-p53 proteins were purified and
dialyzed against 20 mM HEPES buffer (pH 7.0) containing 2 %
glycerol, 1 mM DTT, and 50 mM NaCl.
GST-Pull down assay
To measure the interaction between mouse SIRT1 and p53
peptide, 0.2 mg GST-p53 and 0.2 mg mouse SIRT1 (preincubated
with CK2 with or without TBCA) was incubated with glutathione-
agarose beads (GE) in lysis buffer containing 150 mM NaCl
for 2 hr at room temperature. The beads were washed once
with lysis buffer and twice with RIPA buffer containing 300 mM
NaCl. Proteins retained on the beads were eluted with 2X SDS
sample buffer and subjected to SDS-PAGE. Bound SIRT1 was
visualized by immunoblotting and GST-p53 was visualized by
Ponceau staining.
Proteins, Cell lines and Expression constructs
Wild-type and alanine mutant His-tagged mouse SIRT1 were
constructed in pET-15b prokaryotic expression vector using NdeI
and XhoI restriction sites, expressed in E.coli, and purified on
Ni
2+-NTA beads (Qiagen) following the manufacturer’s protocol.
GST fusion constructs of full-length and truncated mouse SIRT1
were generated by PCR amplification and subcloned into pGEX
4T-3 vector using SalI and XhoI sites. All GST-fusion constructs
were transformed into BL21 competent cells and the recombinant
proteins were purified and dialyzed as described above. To
produce GST-PC, optimized CK2 substrate (Fig. 2B), nucleotides
corresponding to RRRDDDSDDD were ligated into pGEX 4T-3
vector using Bam H1 and XhoI sites. To produce the mammalian
SIRT1 expression vectors, WT and mutant mouse SIRT1 coding
sequences were subcloned into pcDNA6.0 (Invitrogen) and FLAG-
CMV expression vector (Sigma) using KpnI and XhoI sites. Wild-
type and kinase-dead dominant negative CK2 a’ expression
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Ontario, Canada). H1299 non-small cell lung cancer cells, Hela
cervical cancer cells, HEK 293T cells, Hepa 1–6 mouse hepatoma
cell, and U2OS human osteosarcoma cells were maintained in
DMEM medium supplemented with 10% FBS. The expression
vector for FLAG-RelA/65 (1–313) was previously published [38].
Apoptosis assay
To measure p53-dependent apoptosis, we co-transfected H1299
cells with expression vectors for p53 and pcDNA (empty), WT or
4A mutant SIRT1 and K
K plasmid. Transfected cells were
selected using autoMax system (Miltenyi Biotec Inc.) 36 hr after
transfection. After a further 24 hr, the cells were treated with
etoposide (20 mM) for 24 hr and apoptosis was measured by the
cell death detection ELISA Plus (Roche) according to the
instruction manual.
Immunoblotting and immunoprecipitation assays
Whole cell lysates were prepared by adding a lysis buffer
containing phosphate buffered saline supplemented with 1 %
Triton X-100, protease and phosphatase inhibitor cocktails
(Roche). Extracts were separated by 4–12 % SDS-PAGE gels,
transferred to nitrocellose mambrane and probed with primary
antibodies as indicated. To immunoprecipitate, cells treated as
indicated were extracted with lysis buffer and incubated with
recommended amount of primary antibodies by manufacturer for
overnight at 4uC and then further incubated with protein A/G
agarose beads (Pierce) for 2 hrs. These beads were loaded onto
Micro Bio-Spin chromatography columns (Bio-Rad), washed four
times with lysis buffer, which was then removed by centrifugation.
Immunoprecipitated proteins were denatured with SDS-sample
buffer and released from the column by centrifugation. Antibodies
for SIRT1 (Upstate Biotechnology), Acetyl-Lys (Cell Signaling
Technology), CK2a and a’ (Santa Cruz Biotechnology) were
purchased from commercial sources.
P-S649 antibody generation
The phosphospecific antibody was manufactured by 21st
Century Biochemicals (Marlborough, MA). Briefly, a peptide
corresponding to the sequence C-Ahx-IFHGAEVY[pS]D-amide
was manufactured by Fmoc chemistry, HPLC purified to.90%,
and the mass and sequence verified by nanospray MS and CID
MS/MS, respectively. This peptide was conjugated to a carrier
protein and was used to immunize two New Zealand rabbits. After
multiple boosts and bleeds, serum that detected the target via
western blots was pooled, immunodepleted by passing the serum
over cross-linked agarose conjugated with unmodified peptide, and
subsequently affinity purified using phosphopeptide-cross-linked
agarose.
Si RNA transfection
SMART pool siRNA (Dharmacon, Inc.) for both CK2 a and a’
were transfected into HEK293 T cells using Lipofectamine 2000.
The siRNA sequences for CK2 a is: GCAUUUAGGUGGAGA-
CUUC, GGAAGUGUGUCUUAGUUAC, GCUGGUCG-
CUUACAUCACU and AACAUUGUCUGUACAGGUU. The




Table S1 A list of kinase inhibitors used to screen for Sirt1
kinases.
Found at: doi:10.1371/journal.pone.0006611.s001 (0.07 MB
PDF)
Figure S1 GST-p53 acetylated by PCAF was immunoblotted
with acetyl-K382 antibody.
Found at: doi:10.1371/journal.pone.0006611.s002 (0.10 MB
PDF)
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